Submit Deal

IMMUNICUM AB

Summary

Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies.

Deals Overview

Total Deals1

Valued Deals1

Total Value£ 54 M

Avg. Deal Size£ 54 M

Market Context

Senior Management

Sven Rohmann
CEO
Michael Oredsson
Chairman

Sort

allen & overy

HQ - London

legal advisors (1)

1 Shared Deal

1 Opposite

£ 54 M

Total Value

van lanschot kempen

financial advisors (1)

1 Shared Deal

1 Opposite

£ 54 M

Total Value

cederquist

legal advisors (1)

1 Shared Deal

1 Opposite

£ 54 M

Total Value

paues aberg communications

pr advisors (1)

1 Shared Deal

1 For

£ 54 M

Total Value

trophic communications

HQ - Munich

pr advisors (1)

1 Shared Deal

1 For

£ 54 M

Total Value

asperion

commercial advisors (1)

1 Shared Deal

1 For

£ 54 M

Total Value

erik penser bankaktiebolag

financial advisors (1)

1 Shared Deal

1 For

£ 54 M

Total Value

delphi

legal advisors (1)

1 Shared Deal

1 For

£ 54 M

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy